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Abstract: Psychostimulant drugs have for decades been considered the cornerstone of ADHD 
treatment. Non-stimulant drugs have also been reported successful. However, many controlled 
studies exclude patients with comorbidities typical for patients seen in clinical setting. Many patients 
are also considered non-responders to medication. Current knowledge might not be directly useful 
to clinicians. The present article reviews the literature on pharmacological and psychotherapeutic 
treatment in adult ADHD emphasizing comorbidity and other clinically important factors, as well 
as ADHD speciﬁ  c outcomes. Thirty-three relevant studies of pharmacotherapy and three studies 
of psychotherapy were included. Most subjects had little current comorbidity, but some studies 
included subjects with substance use disorder. Signiﬁ  cant effect of treatment on ADHD symptoms 
was found in most studies using pharmacotherapy and all studies of psychotherapy. Both positive 
and negative effects on comorbid anxiety and depression measures were reported. Pharmacotherapy 
did not seem to have effect on substance use disorder. Few pharmacotherapy studies conducted any 
long-term follow-up; two studies that did, found that most subjects had discontinued medication. 
A clear-cut dose-respons relationship was not substanciated. In conclusion, clinicians have good 
support for both pharmacological and psychotherapeutic treatment of ADHD in adults, but should 
take additional measures to deal with comorbidities as well as treatment adherence.
Keywords: ADHD, adults, treatment, stimulants, psychotherapy, comorbidity
Introduction
Attention-deﬁ  cit/hyperactivity disorder (ADHD) has for a long time been recognized 
in children. During the last couple of decades, evidence has conﬁ  rmed that the disor-
der persists into adulthood. The validity of the diagnosis is now recognized (Clarke 
et al 2005; Kooij et al 2005) although the prevalence of the disorder and the degree of 
sustained symptoms as well as the presentation of symptoms in adults are disputed.
As much of the research concerning ADHD has been conducted in America, the 
DSM-IV criteria (American Psychiatric Association 1994) have been widely used, 
while Europeans usually adhere to the ICD-10 criteria (World Health Organization 
1992). Subtle differences between these two sets of criteria could be one of the reasons 
for differences in prevalence, and it is usually held that DSM-IV criteria identify higher 
prevalence than ICD-10 criteria (Tripp et al 1999; Foreman et al 2001).
The possibility of a reduction of symptoms and problems over time in ADHD 
patients has been a matter of concern. A central issue in this debate is the difference 
between syndromatic versus symptomatic persistence. A recent meta-analysis (Faraone 
et al 2006) suggested a higher rate of persistence if the subjects were deﬁ  ned as “ADHD 
in partial remission” versus “persistent ADHD”. Most follow up studies, however, 
concern young adults with few subjects up to 30 years. In addition, surprisingly few 
follow up studies report on the treatment received by the subjects.
Adding to the complex questions about syndromatic or symptomatic persistence 
is the fact that comorbidity between ADHD and other psychiatric disorders is very Neuropsychiatric Disease and Treatment 2008:4(1) 178
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common. Studies suggest that up to 90% (Nutt et al 2007) 
of adult patients with ADHD have one or more comorbid 
psychiatric disorder. The most common comorbid disorders 
in adults are anxiety disorders, affective disorders, substance 
abuse and antisocial personality disorder. Developmental 
disorders like autism spectrum disorders, Tourette and tic 
disorders, developmental delay and learning disorders have 
also frequently been reported as comorbid to ADHD. In 
addition they are important differential diagnoses. The high 
prevalence of comorbidity complicates the diagnostic process 
as well as treatment and some studies indicate that high 
rates of comorbidity in adult ADHD contribute negatively 
to the treatment outcome (Jensen et al 1997). A diagnosis of 
ADHD has been associated with functional impairment in 
important life aspects like education, work and relationships 
(Murphy and Barkley 1996; Torgersen et al 2006). Persistent 
ADHD in adults is also common among prison inmates 
(Rasmussen et al 2001), and teens and adults with ADHD 
have an increased frequency of vehicular accidents and other 
driving-related impairments (Barkley et al 2005).
Psychostimulant drugs have for decades been considered 
the cornerstone of ADHD treatment. Many clinicians 
working with ADHD in children, adolescents or adults, have 
experienced impressing effects in some patients, both on 
symptoms and functional impairment. The research literature 
reports good short-term efﬁ  cacy with stimulant drugs like 
methylphenidate and amphetamine for ADHD-symptoms 
in children, adolescents (Smith et al 2000; Schachter et al 
2001) and adults (Faraone et al 2004), and there is some 
evidence for long-term efﬁ  cacy in children (Wilens et al 
2002; MTA Cooperative Group 2004). Efﬁ  cacy for other 
pharmacological agents like atomoxetine, tricyclic antide-
pressants, bupropion and antihypertensives, has also been 
reported (Wilens et al 2002).
In spite of effective psychopharmacological treatment 
of core ADHD symptoms, there is evidence for residual 
symptoms and long lasting functional impairment in many 
adult patients. Research indicates that 20%–50% of adults 
are considered non-responders to stimulants due to insuf-
ﬁ  cient symptom reduction or inability to tolerate adverse 
effects (Wender 1998; Wilens et al 2002). Adult responders 
often show a reduction in 50% or less of the core ADHD 
symptoms (Safren et al 2005). Furthermore, the correlation 
between symptoms and impairment has been reported to be 
low; symptoms predicting less than 25% of the variance in 
impairment (Gordon et al 2006). Weiss and colleagues argue 
that we need more research on effectiveness variables like 
comorbidity, functional impairment, substance abuse and 
compliance or treatment adherence (Weiss et al 2006), to 
evaluate the true clinical impact of the results from short-
term psychopharmacological trials. The importance of this is 
further emphasized by the likelihood of an increased number 
of adult patients with ADHD in psychiatry due to increased 
recognition and awareness (Asherson et al 2007).
The present article reviews the literature on pharmaco-
logical and psychotherapeutic treatment in adult ADHD with 
emphasis on comorbidity as well as ADHD-speciﬁ  c outcome 
measures. Furthermore, the authors will evaluate the effect 
of treatment on other clinically important outcome measures, 
like depression, anxiety, quality of life and long-term treat-
ment adherence or compliance.
Method
Search strategy
We searched for relevant studies on the most commonly used 
and extensively studied stimulants and non-stimulants, and 
psychotherapy, in adult ADHD, in the following electronic 
databases: Pubmed, EMBASE, PsycINFO and the Cochrane 
database until January 2007. Citations from identiﬁ  ed articles 
were also searched for relevant studies.
Inclusion criteria
We used the following criteria for considering papers to 
this review:
1.  All relevant randomized controlled trials.
2.   Adults (>18 years) diagnosed with ADHD criteria accord-
ing to DSM-IV (American Psychiatric Association 1994) 
and ICD-10 (World Health Organization 1992). Some 
studies applying older versions of the two diagnostic 
systems were also included.
3.    Treatment with methylphenidate, dexamphetamine/
amphetamine, atomoxetine, bupropion and imipramine 
administered at any dosage as part of any treatment regi-
men, and psychotherapy of all kinds.
4. Placebo/non-intervention  control  group.
5.    The outcome measures should be clinically important, 
like ADHD symptoms and other features of mental 
health. Trials mainly focusing on variables like driving 
performance, nevrocognitive and neuroimaging effects, 
were not considered in this review.
Results
Thirty-six studies met our criteria for inclusion in this 
review; 33 studies of pharmacotherapy and only 3 studies 
of psychotherapy. A large variety of outcome measures was 
applied. All studies used some kind of ADHD symptom Neuropsychiatric Disease and Treatment 2008:4(1) 179
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rating scale, and some used more than one type of ADHD 
symptom scale or measure. Rating scales that are not ADHD 
symptom speciﬁ  c, like Hamilton anxiety and depression 
scales (HAM-A/D) and Beck depression and anxiety 
inventories (BDI/BAI), were frequently used. The physi-
cian rated Clinical Global Impression (CGI) was the most 
frequently used outcome measure.
There were relatively small numbers of drop-out in most 
of the pharmacological studies. Adverse effects were reported 
to be negligible in all studies.
Pharmacotherapy: methylphenidate
The literature search revealed 18 relevant randomized, 
placebo-controlled trials with methylphenidate in adults with 
ADHD, including one study with dexmethylphenidate (Wood 
et al 1976; Mattes et al 1984; Gualtieri et al 1985; Wender 
et al 1985; Spencer et al 1995, 2005, 2006; Kuperman et al 
2001; Levin et al 2001, 2006, 2007; Schubiner et al 2002; 
Tenenbaum et al 2002; Bouffard et al 2003; Kooij et al 
2004; Carpentier et al 2005; Biederman et al 2006; Reimherr 
et al 2007). Study design features and outcome measures 
are presented in Table 1. Except from two studies from the 
Netherlands (Kooij et al 2004; Carpentier et al 2005) and one 
from Canada (Bouffard et al 2003) all studies are performed 
in the US. The number of participants in the studies varied 
between 8 and 221, and the total number of patients was 991 
(372 females and 619 males; F/M-ratio 0.60). The age ranged 
between 17 and 60 years, and mean age in the samples ranged 
between 27.5 and 42 years.
A majority of the studies had duration of 3–7 weeks, 
while three studies lasted 12–14 weeks. Two studies 
reported follow-up data after 3–6 (Gualtieri et al 1985) and 
6–12 months (Mattes et al 1984), respectively. These two 
studies found that almost none of the patients still used 
methylphenidate at the time of follow-up. The dose of 
methylphenidate varied from a mean dose of 0.2 mg/kg/day 
to 1.1 mg/kg/day. Seven studies were using a high-dose 
(>0.9 mg/kg/day).
We ranked current comorbidity into low, moderate, 
and high according to the following criteria: The study was 
ranked as low in current comorbidity if there was no or very 
sparse information on comorbidity, only lifetime comorbidity 
presented, or low numbers of current comorbid disorders 
like anxiety and mood disorders only. The study was ranked 
as moderate in current comorbidity if the sample had more 
than 25% current comorbid major depression, substance 
abuse or alcohol abuse, and/or personality disorders. Stud-
ies presenting more than 75% current comorbid major 
depression, substance abuse or alcohol abuse, and/or 
personality disorders were ranked as high in comorbidity. 
Eleven studies were ranked as having low rates of comorbid-
ity, including eight studies with no or very sparse information 
on current comorbidity. Three studies were ranked as having 
moderate current comorbidity, showing a substantial number 
of patients with current personality disorders, substance 
abuse/alcohol abuse or affective disorders. Four studies 
with 100% current comorbid substance abuse disorder were 
ranked as high in comorbidity.
Five of the seven studies using high dose methylphenidate 
found significant ADHD symptom relief in favor of 
active drug. One study with a small sample size and one 
large study with high comorbidity found no signiﬁ  cant 
differences. Five out of 10 studies using small/moderate 
doses (<0.9 mg/kg/day) found no significant effects of 
methylphenidate, while the other ﬁ  ve found signiﬁ  cant 
effect. One study using ﬁ  xed doses of 20, 30 or 60 mg/day 
of dexmethylphenidate-extended release (Spencer et al 2006) 
found signiﬁ  cant effect of active drug compared to placebo, 
but did not ﬁ  nd a signiﬁ  cant dose-response relationship, even 
if the highest dose numerically had the highest response. 
Reimherr and colleagues (2007) divided the sample into 
responders and non-responders to methylphenidate, and 
found that the responders ended up with a signiﬁ  cant lower 
dose than non-responders, 57 mg/day versus 75 mg/day, 
respectively.
The placebo responses observed in the latest and largest 
studies are considerably higher than in earlier studies. These 
large placebo responses are shown both in studies with low 
comorbidity, and studies with high levels of comorbidity.
One out of four studies with 100% current comorbid 
substance abuse disorder found initial efficacy for 
methylphenidate (Schubiner et al 2002). However, at the 
end of trial the differences in response rates between drug 
and placebo became nearly identical (methylphenidate 
50% versus placebo 56% at week 12). Reduction in ADHD 
symptoms measured by an 18-item self-report scale did not 
produce signiﬁ  cant differences between methylphenidate and 
placebo at any point in the study. One out of these four studies 
found a tendency towards positive effect on the substance 
abuse. In all these studies the patients received additional 
cognitive behavioral therapy.
A signiﬁ  cant positive effect of methylphenidate treatment 
for comorbid symptoms of anxiety was reported in only one 
study (Bouffard et al 2003), while another study showed a 
statistically signiﬁ  cant negative effect on outcome measures 
of depression and anxiety (Kooij et al 2004). One study Neuropsychiatric Disease and Treatment 2008:4(1) 180
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Table 1  Sample and study design features, and ADHD symptom speciﬁ  c outcome measures, of 18 double-blind, placebo controlled 
studies on methylphenidate (MPH) in adult ADHD
Authors  N  Rank of current  Length  Dose  Efﬁ  cacy; physician  Efﬁ  cacy; patient
   comorbiditya of  study  (mg/kg/dayb) rated  responsec rated  responsec
       and  type   
       of  MPH   
Biederman  141  Low  6 weeks  0.99  MPH   66%
2006       OROS  Placebo    39%
Bouffard  30  Low  5 weeks  0.4–0.6      MPH signiﬁ  cantly better
2003       IR      than  Placebo
Carpentier  25  High  8 weeks  0.2–0.4–0.6  MPH   36%
2005       IR  Placebo    20%
         Not  sign.
Gualtieri  8  Low  5 days  0.6      No sign. effect of MPH
1985       IR
Kooij  45  Moderate  7 weeks  0.9  MPH   51%  MPH   42%
2004        IR   Placebo   18%  Placebo   13%
Kuperman  17  Low  7 weeks  0.9  MPH   50%  No sign. effect of MPH
2001        IR   Placebo   27%
         Not  sign.
Levin ed  10  Low  4 weeks  0.26  No sign.    No sign. effect of MPH
2001       Slow-Release  effect 
Levin fr  65  High  12 weeks  Max. 1,1  MPH   19%  MPH   34%
2006a        Sustained-  Placebo   39%  Placebo   46%
        Release  Not sign.    Not sig.
Levin fr  106  High  14 weeks  0.78  MPH   34%  MPH   47%
2006b        Slow-Release  Placebo   30%  Placebo   55%
          Not sign.    Not sign.
Mattes  26  Moderate  6 weeks  0.7  No sign. effect    No sign. effect
1984       IR   
Reimherr  41  Low  4 weeks  0.83–0.89  MPH   42%  MPH   41%
2007        OROS  Placebo   13%  Placebo   14%
Schubiner  48  High  12 weeks  0.99  MPH   50%  No sign. effect
2002       IR  Placebo    56%
Spencer  23  Low  7 weeks  1.0  MPH   78%
1995       IR  Placebo    4%
Spencer  146  Low  6 weeks  1.1  MPH   68%
2005        IR   Placebo   17%
Spencer  221  Low  5 weeks  0.28–0.41–0.55  MPH   53–61%
2006       d-MPH-ER  Placebo    34%
Teenenbaum  24  Low  3 weeks  0.64      No sign. effect of MPH
2002       IR
Wender  37  Low  5 weeks  0.6  MPH   57%  MPH signiﬁ  cantly better 
1976        IR   Placebo   11%  than Placebo
Wood  11  Moderate  4 weeks  0.28-0.84       Response of MPH  in 8 
1976        IR      out of 11 patients
Abbreviations: IR, immediate release; OROS, osmotic release oral system; d-MPH-ER, dexmethylphenidate-extended release.
aThe study was ranked as low in current comorbidity if there was no or very sparse information on comorbidity, only lifetime comorbidity presented, or low numbers of 
comorbid disorders like anxiety and mood disorders only. The study was ranked as moderate in current comorbidity if the sample had more than 25% current comorbid-
ity on major depression, substance abuse or alcohol abuse, and/or personality disorders. Studies presenting more than 75% current comorbidity on major depression, 
substance abuse or alcohol abuse, and/or personality disorders were ranked as high comorbidity.
bWhen dose is presented in mg/day, these numbers is recalculated to weight-normalized dose (mg/kg/day) using 50th percentile weight for age (Wilens, Spencer, and Bieder-
man 189–202).
cWhen available the measures presented are response rates deﬁ  ned as percent of patients experiencing >30% reduction of ADHD symptoms on an ADHD rating scale, 
and/or much or very much improved on Clinical Global Impression-Improvement (CGI-I). If this deﬁ  nition was not used, we present the response rates as deﬁ  ned by the 
paper.Neuropsychiatric Disease and Treatment 2008:4(1) 181
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showed a negative effect size of –0.54 on anxiety as measured 
by BAI (Tenenbaum et al 2002).
One of the studies included an outcome measure on 
quality of life, the Quality of Life Enjoyment and Satisfaction 
Questionnaire (Q-LES-Q), but there was no effect of 
medication on this measure (Spencer et al 2006).
Pharmacotherapy: amphetamines
The literature search revealed six randomized, placebo-
controlled trials with amphetamines in adults with ADHD 
(Paterson et al 1999; Taylor and Russo 2000; Spencer et al 
2001; Taylor and Russo 2001; Weisler et al 2006; Weiss and 
Hechtman 2006). An overview of the studies is presented in 
Table 2. There was one study from Australia (Paterson et al 
1999) and one from Canada (Weiss and Hechtman 2006); all 
other studies were from the US. The number of participants in 
the studies varied between 17 and 255, and the total number 
of patients was 464 (190 females and 274 males; F/M-ratio 
0.69). The age ranged between 18 and 76 years, and mean 
age in the samples ranged between 35.5 and 41.2 years.
The treatment period ranged from 2 to 20 weeks. The dose 
of amphetamine varied between 10 and 60 mg/day. Three 
studies gave exact information about current comorbidity, 
and in all of this comorbidity were considered to be low.
In all six studies the efﬁ  cacy of amphetamine was superior 
to placebo. In the study by Spencer and colleagues (Spencer 
et al 2001) the percentage of subjects who improved, deﬁ  ned 
as a 30% reduction in the ADHD symptom rating scale, was 
very large compared to placebo (70% vs 7%). In a study 
by Weisler and colleges comprising 255 patients (Weisler 
et al 2006) the efﬁ  cacy of mixed amphetamine salts was 
also signiﬁ  cant better than placebo, however, the number of 
responders was high for placebo too (34%). The study could 
not document a signiﬁ  cant dose-response effect.
None of the studies on amphetamines reported any effect 
on comorbid disorders or symptoms. In one large study of 
four weeks duration (Weisler et al 2006) the drop-out rate 
was 28%, while in a study by Weiss and colleagues (Weiss 
and Hechtman 2006) of 20 weeks duration the drop-out rate 
in the treatment group was 40%.
Table 2  Sample and study design features, and ADHD symptom speciﬁ  c outcome measures, of 6 double-blind, placebo controlled 
studies on amphetamines in adult ADHD
Authors  N  Rank of current  Length  Type of amphetamine  Efﬁ  cacy; physician  Efﬁ  cacy; patient
   comorbiditya  of study  and mean dose  rated responseb rated  responseb
       (mg/day)   
          
Paterson 1999  45  Low  6 weeks  Dexamphetamine  Dexamph.   58%  Dexamph. sign.
        20–25 mg/day  Placebo   <10%  better than Placebo
Spencer 2001  27  Low  3 weeks   Mixed amphetamine salts  MAS   70% 
       (MAS)  Placebo    7%
       53.7  mg/day
Taylor 2001  17  Low  2 weeks  Dexamphetamine      Dexamph. sign.
        10.2 mg/day      better than Placebo
Taylor 2000  22  Low  2 weeks  Dexamphetamine      Dexamph.  48% 
       21.8  mg/day     Signiﬁ  cantly better
            than  Placebo
Weisler 2006  255  Low  4 weeks  Mixed amphetamine salts  MAS-XR 
        -extended release  20 mg   58%
        (MAS-XR)  30 mg   54%
        Fixed dose  40 mg   61%
        20/40/60 mg/day  Placebo   34%
          Effect size   0.8
Weiss 2006  98  Low  20 weeks  Dexamphetamine  Dexamph.   64%
        max. 40 mg/day  Placebo   17%
aThe study was ranked as low in current comorbidity if there was no or very sparse information on comorbidity, only lifetime comorbidity presented, or low numbers of 
comorbid disorders like anxiety and mood disorders only. The study was ranked as moderate in current comorbidity if the sample had more than 25% current comorbid-
ity on major depression, substance abuse or alcohol abuse, and/or personality disorders. Studies presenting more than 75% current comorbidity on major depression, 
substance abuse or alcohol abuse, and/or personality disorders were ranked as high comorbidity.
bWhen available the measures presented are response rates deﬁ  ned as percent of patients experiencing >30% reduction of ADHD symptoms on an ADHD rating scale, 
and/or much or very much improved on Clinical Global Impression-Improvement (CGI-I). If this deﬁ  nition was not used, we present the response rates as deﬁ  ned by the 
paper, or effect size (computed by taking the mean outcome score of active treatment minus the mean outcome score of control/placebo and dividing the result by the 
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Pharmacotherapy: nonstimulants
Our literature search revealed eight randomized, placebo-
controlled trials with non-stimulants in adults with ADHD 
meeting our inclusion criteria. The studies are presented in 
Table 3. Four of the studies used Bupropion in doses up 
to 400 mg/day (Kuperman et al 2001; Wilens et al 2001, 
2005; Adler et al 2006; Levin et al 2006), three studies used 
Atomoxetine/Tomoxetine in doses from 60–120 mg/day 
(Spencer et al 1998; Michelson et al 2003), and one study 
used Desipramine with a mean dose of 147 mg/day (Wilens 
et al 1996). The number of participants ranged from 21 to 
280, and the total number of patients was 888 (338 females 
and 550 males; F/M-ratio 0.61). Mean age in the samples 
ranged between 33 and 42 years. Except from one study with 
100% comorbid substance abuse, we ranked all studies to be 
low in current comorbidity.
Good efﬁ  cacy of the three different drugs was found, but 
only in short term trials. Out of four studies on bupropion, 
two studies found a moderate but robust effect (Wilens et al 
2001, 2005). One study found no signiﬁ  cant differences 
between active drug and placebo (Kuperman et al 2001). 
Neither did another study which included 100% comorbid 
substance abuse (Levin et al 2006).
We found only one study on desipramine, but this study 
had the largest differences in response rates between drug 
and placebo (68% versus 0%) among the eight studies. Two 
large studies of 10 weeks duration on atomoxetine did not 
present response rates, but presented low to moderate effect 
sizes (0.35 and 0.40). Except from a small, 3 weeks study 
on tomoxetine, these studies provide the only evidence for 
the efﬁ  cacy of atomoxetine in adult ADHD. One study on 
atomoxetine found a statistically negative effect on measures 
of depression (Michelson et al 2003).
Psychotherapy
The search revealed three randomized, controlled studies of 
psychotherapy in adult ADHD patients, two from Australia 
(Stevenson et al 2002, 2003) and one from the US (Safren 
et al 2005). The number of participants in the studies varied 
between 31 and 43, and the total number of patients was 109 
Table 3  Sample and study design features, and ADHD symptom speciﬁ  c outcome measures, of 8 double-blind, placebo controlled 
studies on non-stimulants in adult ADHD
Authors  N  Rank of current  Length  Type of drug   Efﬁ  cacy; physician  Efﬁ  cacy; patient
   comorbiditya  of study  and mean   rated responseb rated  responseb
       daily  dose   
          
Kuperman  22  Low  7 weeks  Bupropion SR  Bupropion   64%  No sign. diff. between
2001        Max. 300 mg/day  Placebo   27%  Bupropion and Placebo
         Not  sign. 
Levin  65  High  12 weeks  Bupropion  Bupropion   30%  Bupropion   49%
2006        Max. 400 mg/day  Placebo   39%  Placebo   46%
          Not sign.    Not sign.
Michaelson  280  Low  10 weeks  Atomoxetine  Effect size   0.35
2003-I      60–120  mg/day
Michaelson  256  Low  10 weeks  Atomoxetine  Effect size   0.40
2003-II      60–120  mg/day
Spencer  21  Low  3 weeks  Tomoxetine  Tomoxetine   52%
1998        76 mg/day  Placebo   9.5%
Wilens  41  Low  6 weeks  Desipramine  Desipramine   68%
1996        147 mg/day  Placebo   0%
Wilens  40  Low  6 weeks  Bupropion SR  Bupropion   52%  Bupropion   76%
2001        362 mg/day  Placebo   11%  Placebo   37%
Wilens  162  Low  8 weeks  Bupropion XL  Bupropion   53%  Bupropion sign.
2005        393 mg/day  Placebo   31%  better than Placebo
          Effect size   0.6
aThe study was ranked as low in current comorbidity if there was no or very sparse information on comorbidity, only lifetime comorbidity presented, or low numbers of 
comorbid disorders like anxiety and mood disorders only. The study was ranked as moderate in current comorbidity if the sample had more than 25% current comorbid-
ity on major depression, substance abuse or alcohol abuse, and/or personality disorders. Studies presenting more than 75% current comorbidity on major depression, 
substance abuse or alcohol abuse, and/or personality disorders were ranked as high comorbidity.
bWhen available the measures presented are response rates deﬁ  ned as percent of patients experiencing >30% reduction of ADHD symptoms on an ADHD rating scale, 
and/or much or very much improved on Clinical Global Impression-Improvement (CGI-I). If this deﬁ  nition was not used, we present the response rates as deﬁ  ned by the 
paper, or effect size (computed by taking the mean outcome score of active treatment minus the mean outcome score of control/placebo and dividing the result by the 
pooled standard deviation).Neuropsychiatric Disease and Treatment 2008:4(1) 183
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(44 females and 65 males; F/M-ratio 0.68). Mean age of the 
samples ranged between 36 and 45.5 years.
The treatment period ranged from 8 to 15 weeks, and 
two studies had follow-up periods of 2 and 12 months, 
respectively (Stevenson et al 2002, 2003). All three studies 
included patients on medication, but only two controlled for 
the effect of medication. All three studies applied a form of 
cognitive behavior therapy (CBT), but the various interven-
tions differed. An overview of the studies is presented in 
Table 4. None of the studies presented exact information on 
current comorbidity.
Safren and colleagues (2005) examined the efﬁ  cacy 
of combining medical treatment and cognitive therapy. 
Compared to controls, combined treatment was found to be 
more effective than medical treatment alone. Post treatment 
ADHD symptom speciﬁ  c outcome measures showed 56% 
responders in the combined treatment group versus 13% in 
the control group (medication only). This study also reported 
a signiﬁ  cant positive effect of CBT on measures of anxiety 
and depression.
In two studies by Stevenson and colleagues (2002, 
2003) the efﬁ  cacy of cognitive therapy alone was examined. 
Participants were either on medication or not and were 
randomly assigned to a treatment group or waiting list con-
trol. In both studies outcome measures showed improvement 
in ADHD symptoms. In one of the studies 36% of the patients 
had improved at the end of the treatment period (Stevenson 
et al 2002), and this increased to 50% at follow up after 
12 months (effect size 1, 4). In the other study (Stevenson 
et al 2003) 47% had improved at the end of treatment, but 
this rate decreased to 36% at follow-up two months later.
Neither medication nor comorbidity seemed to have any 
major inﬂ  uence on treatment efﬁ  cacy.
Discussion
Previous reviews (Wilens et al 2002; Dodson 2005) and a 
meta-analysis on pharmacologic treatment of adult ADHD 
(Faraone et al 2004) have shown robust efﬁ  cacy of stimu-
lants on the core symptoms of ADHD in adults, and a dose-
response relationship has been postulated. However, the lack 
of long term placebo controlled studies is emphasized by 
many authors, and in the present review we still could not 
ﬁ  nd any randomized, controlled, long-term pharmacological 
treatment study of adult ADHD. There is robust evidence 
Table 4  Sample and study design features, and ADHD symptom speciﬁ  c outcome measures, of 3 randomized, controlled studies of 
psychotherapy in adult ADHD
Authors N  Rank  ofa   Length   Type of  Efﬁ  cacy: physician  Efﬁ  cacy: patient
    current  of study  psychotherapy  rated responseb rated  responseb
   comorbidity       
          
Safren 2005  31  Low  15 weeks  Cognitive  Effect  size  1.2–1.4  Effect size   1.7
       Behavioural
       Therapy  (CBT)  Responders:
        + continued medication  CBT   56%
        All patients on medication  Control   13%
Stevenson 2002  43  Low  8 weeks  Cognitive      Responders:
      + 2 and  Remediation       Post treatment 36%
      12 months  Programme (CRP)      2 months   55%
      follow-up  + continued      12 months:   50%
       medication
        Med. 22      Effect size   1.4
        Not med. 21   
Stevenson 2003  35  Low  8 weeks  Psychosocial self-      Responders:
      + 2 months  directed intervention      Post treatment 47%
      follow-up  + continued medication      2 months   36%
       Med.  23
        Not med. 12 
aThe study was ranked as low in current comorbidity if there was no or very sparse information on comorbidity, only lifetime comorbidity presented, or low numbers of 
comorbid disorders like anxiety and mood disorders only. The study was ranked as moderate in current comorbidity if the sample had more than 25% current comorbid-
ity on major depression, substance abuse or alcohol abuse, and/or personality disorders. Studies presenting more than 75% current comorbidity on major depression, 
substance abuse or alcohol abuse, and/or personality disorders were ranked as high comorbidity.
bWhen available the measures presented are response rates deﬁ  ned as percent of patients experiencing >30% reduction of ADHD symptoms on an ADHD rating scale, 
and/or much or very much improved on Clinical Global Impression-Improvement (CGI-I). If this deﬁ  nition was not used, we present the response rates as deﬁ  ned by the 
paper, or effect size (computed by taking the mean outcome score of active treatment minus the mean outcome score of control/placebo and dividing the result by the 
pooled standard deviation).Neuropsychiatric Disease and Treatment 2008:4(1) 184
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for the efﬁ  cacy of methylphenidate and amphetamines on 
reducing the core ADHD symptoms over the ﬁ  rst weeks of 
treatment, and in this ﬁ  rst phase the drop-out rates are low 
and there are few problems with adverse effects. The same 
patterns are apparent for the non-stimulants bupropion, 
atomoxetine and desipramine, but the evidence is weaker due 
to fewer studies and lower response rates and effect sizes. 
Only low to moderate effect sizes (0.35–0.40) were found 
in studies of atomoxetine.
Faraone and colleagues (2004) found in their meta-
analysis of efﬁ  cacy of methylphenidate in adult ADHD that 
larger effect sizes was associated with physician ratings of 
outcome and use of higher doses. The present authors also 
found that the use of physician based ratings of outcome still 
is dominating in pharmacological trials of adult ADHD. This 
may lead to an overestimation of efﬁ  cacy possibly due to 
the physician being able to guess treatment assignment, as 
discussed by Schubiner and colleagues (2002).
Findings in our study indicate that the previous postulated 
dose-response relationship in stimulant treatment, in favor if 
high doses, is not so obvious. The dose-response relationship 
seems to be highly variable among patients, indicating that 
the dose must always be individualized for optimal efﬁ  cacy 
and tolerability.
Two of the studies of methylphenidate conducted an open 
long-term follow up and found that very few patients continued 
medication at the time of follow up (Mattes et al 1984; Gual-
tieri et al 1985). These ﬁ  ndings are in accordance with recent 
studies on compliance or treatment adherence. One recent 
report from Canada showed that compliance by the 7th month 
after initial prescription was only 23.5% for methylphenidate 
modiﬁ  ed release and 22.9% for mixed amphetamine salts 
extended release (Capone and McDonnel 2006). Evidence 
from pharmacy claim records also shows that adherence to 
prescriptions for ADHD treatment may be low (Perwien et al 
2004). A report to Norwegian Health authorities on all adult 
ADHD patients treated with stimulant drugs in Norway in 
the period 1997–2003 (1328 patients), show that after two 
years only 20% were still in treatment, in spite of initial 
reports of good effect for most patients (Aanonsen et al 2004). 
Two long-term, open studies on mixed amphetamine salts 
extended release (24 months) and atomoxetine (97 weeks), 
showed rates of treatment adherence at end of study at 34% 
and 32.6%, respectively (Adler et al 2005; Biederman et al 
2005). Therefore, the evidence so far indicates that most adult 
ADHD patients choose to discontinue medication after some 
months, despite an apparently initial good response on core 
ADHD symptoms.
Most studies, both of medication and psychotherapy, had 
low rates of current comorbidity or were lacking exact infor-
mation on this issue. We are therefore still lacking clinically 
important knowledge about the impact of comorbidity on 
response to treatment in adult ADHD. Still, the data on 
methylphenidate indicate that there is no or very little effect 
of stimulants in the treatment of adult ADHD patients with 
current substance abuse, both on core ADHD symptoms and 
the substance abuse.
When evaluating efﬁ  cacy of medication on outcome 
measures for other symptoms than core ADHD symptoms, 
ie, anxiety, depression and quality of life, we could not ﬁ  nd 
evidence for a positive effect. Actually there are indications 
for a negative impact on outcome measures of anxiety and 
depression (Tenenbaum et al 2002; Michelson et al 2003; 
Kooij et al 2004). One explanation for this result may be that 
many studies have low baseline measures on rating scales 
like Hamilton anxiety and depression scales (HAM-A/D) 
and Beck depression and anxiety inventories (BDI/BAI), in 
accordance with the low current comorbidity levels in the 
samples. Another possibility is that many patients really do 
not experience a relief in symptoms of anxiety and depression 
from their ADHD medication, and that this lack of relief, or 
even worsening of symptoms, may have a negative impact 
on treatment adherence in the long run.
The placebo responses observed in newer studies are 
considerably higher than in earlier studies. The reasons 
for these increasing rates of placebo responses are unclear. 
A cohort effect because the disorder has been increasingly 
recognized and treated, or differences in titration of dose 
(forced versus ﬂ  exibly), have been suggested as possible 
explanations (Biederman et al 2006). However, this ﬁ  nding 
is consistent with a large review of 75 placebo-controlled 
trials of antidepressants as treatment for major depression 
(Walsh et al 2002), showing a growing placebo response 
in studies over decades, and that in half of the studies the 
placebo response exceeded 30%. Only year of publication 
was a signiﬁ  cant predictor of placebo response.
There are still very few controlled studies of psycho-
therapy in adult ADHD, but the three studies presented 
here were adequately performed and with promising results 
showing response rates and effect sizes comparable to the 
pharmacologic studies. One study had a long follow-up period, 
showing persisting good results on core ADHD symptoms 
up to one year. Two relevant open studies on psychotherapy 
in adult ADHD (Hesslinger et al 2002; Rostain and Ramsay 
2006) support the ﬁ  ndings in the randomized controlled studies 
indicating efﬁ  cacy of cognitive therapy in adult ADHD.Neuropsychiatric Disease and Treatment 2008:4(1) 185
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The present study indicate that clinicians still have good 
support for treating adult ADHD patients with stimulants 
and to some extent non-stimulants, but both clinicians and 
patients should not be dazzled by the initial good response 
that may come. It is important to follow the patients over a 
long time and to take measures to prevent discontinuation 
of treatment. An individualized titration seems warranted. 
However, the clinician should know that for many patients 
with adult ADHD medication may not have a major impact 
on their problems and symptoms. This is especially the fact 
for patients with current comorbid substance abuse. There 
is growing evidence for the efﬁ  cacy of cognitive behav-
ioral psychotherapy both for medicated and non-medicated 
patients, and clinicians should make an effort to offer their 
patients this type of treatment.
Further controlled research assessing efﬁ  cacy and effec-
tiveness of pharmacological and psychotherapeutic treatments 
in long-term studies should attend to the impact of treatment 
on other measures than core ADHD symptoms, like comor-
bid disorders, quality of life and functional impairment. The 
impact of comorbid disorders and speciﬁ  c ADHD subgroups 
as predictors for treatment outcome should also be focused.
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